S
Spring Bank Pharmaceuticals
A clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, founded in 2002, was a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for viral infections, inflammatory diseases, and specific cancers. The company's core technology was a proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform, which was engineered to selectively target and modulate proteins involved in various diseases.
Read full description
A significant portion of its research and development was initially directed towards treating chronic hepatitis B virus (HBV). Its lead product candidate for HBV was inarigivir soproxil, an orally available immunomodulator. However, in early 2020, the company terminated the development of this drug and its HBV program following unexpected serious adverse events, including a patient death, during a Phase 2b clinical trial.
Following this strategic shift, Spring Bank refocused its efforts on its immuno-oncology pipeline. This portfolio was centered around its STING (STimulator of INterferon Gene) product candidates. The lead asset became SB 11285, an intravenously-administered STING agonist intended for the treatment of advanced solid tumors. The company also had programs for STING antagonists aimed at inflammatory diseases and a STING agonist antibody-drug conjugate (ADC) program for oncology applications.
In July 2020, after a review of strategic options, Spring Bank announced a planned business combination with F-star Therapeutics, a clinical-stage immuno-oncology company. This reverse merger transaction was completed in November 2020, with Spring Bank acquiring F-star and subsequently being renamed F-star Therapeutics, Inc. The combined entity continued to trade on the Nasdaq but under the new ticker symbol "FSTX". The new company's focus was to advance a pipeline of tetravalent bispecific antibodies from F-star, alongside Spring Bank's STING agonist, SB 11285. As part of the merger, Spring Bank stockholders received contingent value rights (CVRs) related to the future success of its STING programs.
At a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Milford, United States
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 25.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Bank, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 1 company, latest Jul 2020
- Capital deployed
- —
- Preferred round
- MERGER
Latest news
Press, funding announcements and product moves mentioning Spring Bank Pharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Jul 2020 | $0 | — | F-star Biotech | — |
| IPO✓Exit | May 2016 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Spring Bank Pharmaceuticals is 280 monthly website visits, down 47.2% over the last three months. Spring Bank Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Other known investors1 additional known investor
F-star Biotech
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spring Bank Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spring Bank Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.